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Purpose: The article reports a wet milling process, where the planetary ball mill was combined 
with pearl milling technology to reach nanosize range of meloxicam (Mel; 100–500 nm). The main 
purpose was to increase the dissolution rate and extent of a poorly water-soluble Mel as nonsteroidal 
anti-inflammatory drug as well as to study its permeability across cultured intestinal epithelial cell 
layers.
Methods: Viscosity of milled dispersion and particle size distribution and zeta potential of 
Mel were investigated and differential scanning calorimeter and X-ray powder diffractometer 
were used to analyse the structure of the suspended Mel. Finally in vitro dissolution test and in 
vitro cell culture studies were made.
Results: It was found that the ratio of predispersion and pearls 1:1 (w/w) resulted in the most effec-
tive grinding system (200-fold particle size reduction in one step) with optimized process parameters, 
437 rpm and 43 min. Nanosuspension (1% Mel and 0.5% poly[vinyl alcohol]) as an intermediate 
product showed a stable system with 2 weeks of holding time. This optimized nanosuspension 
enhanced the penetration of Mel across cultured intestinal epithelial cell layers without toxic effects.
Conclusion: The dissolution rate of Mel from the poly(vinyl alcohol) stabilized nanosuspension 
justified its applicability in the design of innovative per oral dosage form (capsule) in order to 
ensure/give a rapid analgesia.
Keywords: nanonization, meloxicam, milled dispersion, milling efficiency, zeta potential, 
intermediate product
Introduction
The planetary ball milling belongs to the group of high-energy milling methods. The 
process is mainly used in laboratory-scale research work. It is a common technique 
for dry milling,1,2 nevertheless it is also suitable for wet grind.3–5 Dry milling with this 
technique is usually used for micronization with a particle size range of 1–2,000 µm.6 
In general, additives are not required for micronization, but for dry nanonization, 
application of them and a long milling time (2–4 h) can be necessary. Additives decrease 
the cohesion between the nanosize particles and the collision energy during the mill-
ing process; thereby, the risk of the decomposition of the active agent can be reduced.7
Wet milling is a top–down process, where the raw material is broken down via 
mechanical forces. In this method, a sufficiently concentrated dispersion of drug 
particles in an aqueous or nonaqueous liquid medium is treated. Increased mill 
capacity, lower energy consumption, and easier handling of materials can be perceived 
as advantages of the process. However, it must be said, in the course of the milling 
process, increased wear of the milling medium and corrosion can occur, and the 
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instability of the active agent must be taken into account. 
Wet milling is applicable for micronization in the particle 
size range of 1–50 µm, in this case, colloid mill, toothed 
high-shear inline mixers, and cone mill can be used,8 but 
for nanonization, high-pressure homogenization (1–20 µm) 
and pearl milling technique (20–200 nm)9–11 can be applied. 
It should be noted that in case of high-pressure homog-
enization and pearl milling techniques, the preparation of 
pretreated dispersions (particle size reduction to 1–10 µm) 
is required to reach the nanosize range.
The pearl milling process has been proven to be a robust 
technique for the production of nanoparticle suspension of 
poorly water-soluble drugs.12 With this method, nanosuspen-
sions are produced through the use of high-shear media or 
pearl mills. Pearl milling is a continuous process wherein the 
drug suspension is pumped through the milling chamber in 
order to reduce the particle size of the suspended material. 
The milling medium consists of glass, zirconia, or highly 
cross-linked polystyrene resin.13 The physical characteris-
tics of the resulting nanocrystals depend on the number and 
size of the milling pearls, the amount of the drug, and the 
stabilizer(s).14,15
Thanks to the high efficiency of a smaller pearl size16 
and the high mechanical forces of the planetary mill, Retsch 
GmbH (Haan, Germany) recommends the combination of the 
planetary ball and pearl milling as a novel milling technique 
in order to prepare drug nanodispersions.17 In the literature, 
there are few articles about the combinative method, where 
various active agents were co-milled. In the presence of 
d-tocopherol polyethylene glycol 1000 succinate as a stabi-
lizer agent, nanoparticle range was achieved; however, the 
production efficiency was very low.18,19
Our team uses different milling techniques (dry and wet) 
in order to nanonize different water-insoluble drugs, eg, 
meloxicam (Mel), to provide a faster dissolution, a higher 
saturated concentration, a faster absorption, and, in this 
context, a better bioavailability. Mel as a nonsteroidal anti-
inflammatory agent is often used in malignant and nonma-
lignant pain therapy, but its bioavailability is unsatisfactory 
thanks to its poor solubility in the gastrointestinal tract. One 
strategy to address these problems is the particle size reduc-
tion (eg, nanonization), which increases the dissolution rate 
of the poorly soluble drug resulting in faster absorption and 
faster action in pain therapy.
In our earlier studies, we investigated the applicability of 
the combined wet milling technique,20–23 and these prelimi-
nary studies showed that for the nanonization of Mel, PVA 
as a stabilizer agent and an increased milling time (.50 min) 
were required. The influence of milling time was also studied 
on the particle size distribution, crystallinity, and dissolution 
rate of Mel.
During the use of the combined wet milling technique, 
the type and amount of PVA are very important because it 
has a dual role. On the one hand, it promotes the grinding 
efficiency in the concentrated predispersion, and on the other 
hand, it stabilizes the milled dispersion and later the final 
nanosuspension in a diluted medium.
PVA is a nonionic polymer with very different molecular 
weights. It is frequently used as a stabilizer agent.20 Polymer 
adsorption on the solid–liquid interface can be influenced 
by the various conformations of the polymer chains and the 
interaction of the polymer segments with the solvent and the 
surface of the solid as well. PVA with low molecular weight 
(about 20,000 g/mol) is adsorbed on the colloid particles and 
thus stabilizes the colloid suspension (coating the particles 
and providing the repulsion among them), whereas PVA with 
high molecular weight (about 1,000,000 g/mol) flocculates 
the dispersed systems.24
The prediction of permeability features of drug candi-
dates across biological barriers is of great importance in the 
early phase of drug development.25 Oral drug formulations 
are the most widespread in human therapy, and therefore 
intestinal drug absorption is the most studied in pharma-
ceutical research. The human Caco-2 cell line, presenting 
many of the structural and functional aspects of the epithe-
lium of small intestine, is a routinely used culture model of 
intestinal drug penetration showing good correlation with 
in vivo data.26
The aim of this work was to optimize the process param-
eters (pearl amount, milling time, and rotation speed) of the 
combined wet milling technique (planetary ball and pearl 
milling), using Mel as an active agent and PVA as a stabiliz-
ing agent in the predispersion. We basically investigated the 
influence of the amount of low molecular weight PVA on 
the grinding efficiency in concentrated predispersion. Our 
aim was also to get to know the effect of mechanical forces 
on polymer viscosity and drug–polymer interaction as well. 
To describe the stability of nanosuspensions, their particle 
size was monitored for 2 weeks. Furthermore, the optimized 
Mel formulations were tested on the cell culture model of 
intestinal epithelium.
The novelty of this study is the application of PVA and 
the combined wet milling process and optimization of the 
amount of the additive and the process parameters in order 
to produce Mel nanosuspension (particle size range of 
100–500 nm) without any pretreating procedure.
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Materials and methods
Materials
Mel was obtained from EGIS Ltd. (Budapest, Hungary). 
PVA-Mowiol 4-98 (M
w
 ~27,000) (Sigma-Aldrich Co. LLC, 
St Louis, MO, USA) was used as a stabilizing agent. Reagents 
were purchased also from Sigma-Aldrich. Zirconium oxide 
(ZrO
2
) beds with a diameter of 0.3 mm were obtained from 
Netsch (Netsch GmbH, Selb, Germany). All reagents were 
purchased from Sigma-Aldrich, Ltd. (Budapest, Hungary) 
for the in vitro cell culture experiments, unless otherwise 
indicated.
Methods
combined wet media milling
Optimization of process parameters
The samples were milled with the steel jar with 50 mL 
volume of the Retsch PM 100 planetary ball mill (Retsch 
PM 100 MA, Retsch GmbH) combined with 0.3 mm ZrO
2
 
beads as the grinding media. The concentrated (10% w/w) 
predispersions (2 g of Mel suspended in 18 g of dispersant 
medium containing PVA) were added to the ZrO
2
 beads. 
In the first step, the effect of different amount of ZnO
2
 pearls 
on the particle size reduction was investigated. The ratio of 
the amount of predispersion and pearls (w/w) was 1:0.5, 1:1, 
1:2, and 1:4; and the milling times were 10, 30, and 50 min. 
In these cases, the concentration of PVA solution was 2.5% 
(w/w), and the rotation speed was 400 rpm. In the second 
step, design and analysis of experiments with 3 levels were 
used to optimize the milling time (10, 30, and 50 min) and 
the rotation speed (200, 350, and 500 rpm) as independent 
variables. The amount of the pearls was chosen on the basis 
of the optimization study. The temperature of the samples 
was measured immediately after milling. This value did not 
exceed 39°C.
Optimization of PVa concentration
Various amounts of PVA (2.5%–7.5%) were applied to pre-
pare the concentrated predispersions. The concentration of 
the PVA solutions was increased in the half percent range. 
Mel content was 10% (w/w), and the optimized process 
parameters were used during the milling. The degree of 
particle size reduction and particle size distribution were the 
main factors for the optimization of the PVA concentration 
(Figure 1).
The concentrated milled dispersions were filtered by a 
sieve with 150 µm mesh size in order to remove the pearls. 
For the washing of the pearls, 180 g of distilled water was 
used. In all cases, the milled dispersions were 10-fold diluted 
products with 1% of Mel (w/w) content. The samples were 
selected on the basis of the particle size range (100–500 nm) 
and the holding time (2 weeks).
investigation of the samples
Particle size measurement
The volume-based particle size distribution was measured by 
laser diffraction (Mastersizer S 2000, Malvern Instruments 
Ltd, Worcestershire, UK) with the following parameters: 
300RF lens; small volume dispersion unit (1,000 rpm); 
refractive index for dispersed particles 1.596; and refractive 
index for dispersion medium 1.330. Water was used as a 
dispersant, and the obscuration was in the range of 11%–16% 
for all measurements. In all cases, the particle size distribu-
tions were characterized by the d(0.1), d(0.5), and d(0.9) 
(where, eg, d(0.5) is the maximum particle diameter below 
which 50% of the sample volume exists), and the Span values 
were calculated according to equation. A high Span value 
(.1) denotes a broad particle size distribution.27
 
Span
(0.9) (0.1)
(0.5)
= d d
d
−
 
rheological measurement
To investigate the viscosity changes during the milling 
process, the initial and milled PVA solutions and the con-
centrated milled dispersions were used. Rheological measure-
ments were carried out with Physica MCR101 rheometer 
&RQFHQWUDWHGSUHGLVSHUVLRQRI0HO±RI39$XSWRRIZDWHU
&RQFHQWUDWHGPLOOHGGLVSHUVLRQ
1DQRVXVSHQVLRQDVVWDEOHLQWHUPHGLDWHSURGXFWKROGLQJWLPHZHHNV
'LOXWHGGLVSHUVLRQRI0HORI39$XSWRRIZDWHU
&RPELQHGZHWPLOOLQJZLWKRSWLPL]HGSURFHVVSDUDPHWHUV
IROGGLOXWLRQHOLPLQDWLRQRIWKHPLOOLQJPHGLD
6HOHFWLRQRIVDPSOHZLWKSUHGHWHUPLQHGVL]HUDQJH±QP
Figure 1 Protocol of sample preparation for the optimization of PVa content.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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(Anton Paar, Graz, Austria). A concentric cylinder measuring 
device with a diameter of 17 mm was used. The flow curves 
of the samples were determined at 25°C, where the shear rate 
was increased from 0.1 to 100 L/s. The shearing time was 
300 sec. In this paper, viscosity values were given at 100 L/s 
shear rate. Two parallel measurements were run.
Zeta potential
The zeta potential of the dispersions was measured using 
a Malvern Zeta Nano ZS (Malvern Instruments Ltd). For 
the zeta potential determination, Malvern DTS 1070 folded 
capillary cell was used. The diluted milled dispersions were 
further diluted with water (25-fold) for the measurements.
raman spectroscopy
For the investigation of Mel degradation as a function of 
the pearl amount and milling time in the dispersion, Raman 
spectra were acquired with a Thermo Fisher DXR Dispersive 
Raman (Thermo Fisher Scientific Inc., Waltham, MA, USA) 
equipped with a CCD camera and a diode laser operating 
at a wavelength of 532 nm. Raman measurements were 
carried out with a laser power of 4 and 8 mW at 25-µm slit 
aperture size on a 2 µm spot size. The spectra of the indi-
vidual substances as Mel and PVA were collected using a 
2-sec exposure time, a total of 48 scanning in the spectral 
range of 3,300–200 cm–1 with cosmic ray and fluorescence 
corrections.
Morphology of the particles (scanning electron 
microscopy)
For the investigation of the morphology of the particles, 
the diluted milled dispersions were dried in a vacuum dryer 
(Binder GmbH, Tuttlingen, Germany) at 40°C in order to 
obtain solid products for physicochemical investigations. 
After drying, the shape and surface characteristics of the 
samples were visualized using a scanning electron micro-
scope (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan). 
The samples were sputter-coated with gold–palladium under 
an argon atmosphere, using a gold sputter module in a high-
vacuum evaporator, and the samples were examined at 10 kV 
and 10 mA. The air pressure was 1.3–13 MPa.
Differential scanning calorimetry (Dsc)
DSC measurements were carried out with a Mettler Toledo 
DSC 821e thermal analysis system with the STARe thermal 
analysis software V9.0 (Mettler Inc., Schwerzenbach, 
Switzerland). Approximately 2–5 mg of pure Mel and PVA 
as well as dried samples were examined in the temperature 
range of 25°C–270°C. The heating rate was 10°C/min in the 
presence of argon as a carrier gas with a flow rate of 10 L/h.
X-ray powder diffraction analysis (XrPD)
The crystallinity state of Mel in the dried samples was evalu-
ated by XRPD. XRPD patterns were produced by a Bruker 
D8 Advance diffractometer (Bruker AXS GmbH, Karlsruhe, 
Germany) system with Cu K λI radiation (λ=1.5406 Å). 
The samples were scanned at 40 kV and 40 mA from 3 to 
40 2θ, at a step time of 0.1 sec, and a step size of 0.010°. 
The instrument was calibrated by using SI standard. 
The semiquantitative determination of Mel crystallinity 
(Cryst. %) was performed using the total area under the 
curve of 3 characteristic peaks (13.06, 14.94, and 18.61 
2θ) of Mel. The area under the curve value of the peak of 
raw material without milling (rawMel) and the dried milled 
dispersions (MelD) was calculated and compared according 
the following formula:
 
Cryst. % = AUCMelD
AUCrawMel
100×
 
Drug content determination
The loss of weight of Mel was controlled in the milled 
suspension. Seventy-five milligram of the liquid products 
with 0.75 mg of theoretical Mel was dissolved in 100 mL of 
phosphate buffer pH 7.4±0.1. The sample was stirred with a 
magnetic stirrer at 25°C for 24 h and then filtered (0.1 µm, Fil-
terBio PES Syringe Filter) (Labex Ltd., Budapest, Hungary), 
and the concentration of the dissolved Mel was analyzed 
spectrophotometrically (Unicam UV/VIS) (Thermo Fisher 
Scientific Inc.) at 364 nm wavelength. The investigations 
were repeated 3 times.
in vitro dissolution test
To determine the dissolution extent of Mel from disper-
sions, the paddle method (USP dissolution apparatus, type II 
Pharma Test, Heinburg, Germany) was used. About 750 mg 
of the dispersion with 7.5 mg of Mel (therapeutic dose) was 
filled into hard gelatin capsules within 5 sec and put promptly 
into the medium. The medium contained 900 mL of artificial 
gastric fluid at pH 1.2±0.1 and intestinal fluid (pH 6.8±0.1). 
The paddle was rotated at 100 rpm, and sampling was 
performed up to 60 min. The Mel contents of the samples 
were determined using a spectrophotometer (ATI-UNICAM 
UV/VIS Spectrophotometer) at 362 nm (gastric juice) and 
364 nm (enteric fluid). The number of parallel runs was 3.
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in vitro cell culture studies
human caco-2 intestinal epithelial cell line
Caco-2 intestinal epithelial cell line was purchased from 
ATCC (Manassas, VA, USA) (cat. no HTB-37) and used 
until passage 60 for the experiments. The cells were grown 
in DMEM (Gibco, Life Technologies, Carlsbad, CA, USA) 
and supplemented with 10% fetal bovine serum (Pan-Biotech 
GmbH, Aidenbach, Germany) and 50 µg/mL gentamycin 
in a humidified incubator with 5% CO
2
 at 37°C. All plastic 
surfaces were coated with 0.05% rat tail collagen in sterile 
distilled water before cell seeding in culture dishes and the 
medium was changed every 2 days. The stock solutions for 
cell culture experiments were the following: Mel, 100 mg/
mL; PVA, 5% (w/w), and 3 products containing 100 mg/mL 
Mel with various amounts of PVA (2.5%, 5%, or 7.5%). The 
working solutions were diluted in the cell culture medium 
or Ringer–Hepes buffer and contained 1 mg/mL of Mel for 
the Mel and formulation groups. The final concentrations of 
PVA were 0.025%, 0.05%, and 0.075% (w/w).
cell viability measurement by impedance
Impedance was measured at 10 kHz using the RTCA-SP 
instrument (RTCA-SP instrument, ACEA Biosciences, San 
Diego, CA, USA). This method is label-free, noninvasive 
and follows cell adherence, growth, number, and viability 
real time. We have successfully tested the cellular effects 
of peptides and pharmaceutical excipients by impedance 
kinetics.28–30 For background measurements, a 50 µL cell 
culture medium was added to the wells; then, cells were 
seeded at a density of 6×103 cells/well to 96-well plate with 
gold electrodes (E-plate 96, ACEA Biosciences) coated with 
collagen. Cells were cultured for 5 days in a CO
2
 incubator 
at 37°C and monitored every 10 min until the end of experi-
ments. When cells reached the plateau phase of growth, they 
were treated with Mel, PVA, and Mel+PVA samples diluted 
in a cell culture medium, and the effects were followed for 
8 h. Triton X-100 detergent (1 mg/mL) was used as a refer-
ence compound to induce cell toxicity. Cell index was defined 
as R
n
-R
b
 at each time point of measurement, where R
n
 is the 
cell–electrode impedance of the well when it contains cells 
and R
b
 is the background impedance of the well with the 
medium alone.
Permeability study on cell culture model
Transepithelial electrical resistance (TEER) reflects the tight-
ness of the intercellular junctions closing the paracellular 
cleft, and therefore reflects the overall tightness of cell layers 
of biological barriers. TEER was measured every 2 days to 
check the barrier integrity by an epithelial volt-ohmmeter 
(World Precision Instruments, Sarasota, FL, USA) combined 
with STX-2 electrodes and was expressed relative to the 
surface area of the monolayers as Ω×cm2.
Caco-2 cells were seeded onto Transwell inserts (polycar-
bonate membrane, 0.4 µm pore size, 1.12 cm2 surface area; 
Corning Life Sciences, Tewksbury, MA, USA) and cultured 
for 3 weeks.31,32 The culture medium was changed and TEER 
was checked every second day.
For the permeability experiment, inserts were transferred 
to 12-well plates containing 1.5 mL Ringer–Hepes buffer 
in the lower (basal) compartments. In the upper (apical) 
compartments, the culture medium was replaced by 0.5 mL 
buffer containing treatment solutions of Mel, PVA, and Mel 
formulation groups for 1 h. Permeability marker molecules 
fluorescein (10 µg/mL; M
w
: 376 Da) and albumin (10 mg/mL; 
M
w
: 65 kDa) labeled with Evans blue (167.5 µg/mL) were 
used for verifying the cell layer integrity. Treatment solu-
tions from both compartments were collected and the Mel 
level was detected using a Thermo Spectronic Helios Alpha 
UV-Vis spectrophotometer (Thermo Fisher Scientific Inc.).
The concentrations of the permeability marker molecules 
of collected samples were determined by a fluorescence 
multi-well plate reader (Fluostar Optima, BMG Labtech, 
Offenburg, Germany; for fluorescein: excitation wavelength, 
485 nm; emission wavelength, 535 nm and for Evans blue-
labeled albumin: excitation wavelength, 584 nm; emission 
wavelength, 680 nm).
The apparent permeability coefficients (P
app
) were calcu-
lated as described previously.28 Briefly, the cleared volume was 
calculated from the concentration difference of the tracer in 
the lower/basal compartment (Δ[C]
B
) after 30 min and upper/
apical compartments at 0 h ([C]
A
), the volume of the lower/
basal compartment (V
B
, 1.5 mL) and the surface area available 
for permeability (A, 1.1 cm2) using the following equation:
 
P
C V
A C tapp
A A
L
(cm/s)
[ ]
=
∆ ×
× × ∆[ ]
 
Determination of holding time
Since the diluted dispersions are intermediate products, it 
was necessary to specify the “holding time” of the sample 
through the particle size distribution. The products were 
stored in sealed glass bottles at room temperature (25°C±1°C) 
for 2 weeks. The particle size distribution of the Mel in the 
samples was analyzed on the day of production (day 0) and 
after 14 days of storage.
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statistical analyses
Data were expressed as mean±SD, and groups were com-
pared by using Student’s t-test. For the evaluation of cell 
culture results, GraphPad Prism 5.0 software (GraphPad 
Software Inc., San Diego, CA, USA) was used. All cul-
ture data presented are mean±SD; values were compared 
using analysis of variance followed by Bonferroni post-
test. Differences were considered statistically significant 
when p,0.05.
Results and discussion
Optimization of process parameters (pearl 
amount, milling time, and rotation speed)
The effect of pearl amount and milling time on particle size 
of d(0.5) was investigated. This study was performed using 
2.5% PVA solution.23 The ratio of the concentrated predisper-
sion (2.0 g of Mel+18.0 g of PVA aqueous solution) and pearl 
amount was different: 1:0.5, 1:1, 1:2, and 1:4 (w/w). It can be 
established that the pearl amount and the milling time have 
a great effect of on the d(0.5) value (Table 1). The milling 
efficiency was not satisfactory in case of ratio 1:0.5, but it 
increased linearly on increasing the amount of the milling 
media and the milling time except in case of ratio 1:4. It was 
found that the increase of the amount of the milling media 
(up to 1:2 w/w or more) causes gray coloring because of the 
high friction between the pearls and the wall of the steel jar. 
Therefore, the pearl milling amount was optimized at the 
ratio of 1:1 (20 g of concentrated predispersion and 20 g of 
pearls), and the milling time was investigated as an indepen-
dent variable in the factorial experimental design. Another 
advantage of the small amount of the grinding media may 
be the reduction of the product loss.
During the factorial experimental design, the influence 
of the milling time and the rotation speed on the particle size 
reduction was investigated. The ratio of the predispersion 
and the pearls was also 1:1 (w/w). Figure 2 shows that the 
efficiency of the particle size reduction was improved by 
increasing the milling time and the rotation speed. Based on 
the results, 437 rpm and 43 min are the optimal parameters 
of the milling process.
Optimization of PVa concentration
Influence of PVA amount on the milling effectiveness
Concentrated predispersions with different PVA amounts 
(2.5%–7.5%) were milled with optimized parameters 
(2 g of Mel+18 g of PVA aqueous solution, 20 g pearls, 
437 rpm, 43 min). The results show (Figure 3) that the lower 
Table 1 Particle size of Mel (d[0.5]) in milled dispersion as a func-
tion of different pearl amounts and milling time (d[0.5] of raw Mel 
was 34.260±4.860 µm)
 Ratio of predispersion and pearl amount (w/w)
1:0.5 1:1 1:2 1:4
Particle size (µm)
10 min 4.015±0.06 2.426±0.029 2.383±0.016 0.149±0.03
30 min 0.293±0.008 0.145±0.007 0.190±0.003 0.137±0.006
50 min 0.202±0.003 0.140±0.004 0.140±0.002 0.130±0.004
Note: d(0.5) is the maximum particle diameter below which 50% of the sample 
volume exists.
Abbreviations: Mel, meloxicam; w/w, weight/weight (concentration).
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Figure 2 Three-dimensional illustration of the particle size changes during the 
second factorial experimental design.
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Figure 3 Particle size reduction effectiveness according to PVa concentrations and 
the span values for the demonstration of particle size distribution.
Notes: d(0.5) and d(0.9) is the maximum particle diameter below which 50% and 
90%, respectively, of the sample volume exists. span is the calculated value for a 
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Abbreviation: PVa, poly(vinyl alcohol).
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combined wet milling process to produce nanosuspension
concentration of PVA (from 2.5% to 3.5%) was not suitable 
to reach the nanosize range (100–500 nm). A higher concen-
tration of PVA (6.0%–6.5%) also resulted in unsatisfactory 
milling effectiveness. Over 6.5% a robust protecting layer 
was probably formed on the solid particles, and nanoniza-
tion was not possible. The curve of the Span follows the 
different particle size distribution of the samples. The best 
particle size distribution was measured in the range of 4.0% 
and 5.5% of PVA. Based on the results, the concentrated 
milled dispersion containing 5.0% of PVA was selected as 
the optimized PVA amount.
Influence of PVA amount on the physicochemical 
properties of milled dispersions
After the optimization of the wet milling process and the PVA 
amount, in order to understand the influence of the amount of 
PVA on the physicochemical properties of the samples, the 
milled dispersions with 3 different concentrations of PVA 
were investigated. These were the following: 2.5%, 5.0% 
(as optimized), and 7.5% of PVA.
Viscosity changes during the milling
In order to exclude the viscosity changes because of the high 
mechanical forces during the milling, the viscosity of 3 raw 
PVA solutions (2.5%, 5%, and 7.5%) was investigated before 
the milling process, after the process (437 rpm, 43 min), 
and after the milling with the addition of Mel. The polymer 
solutions showed Newtonian flow behavior as their shear 
viscosity was independent of the applied shear rate. The 
viscosity of the polymer solutions increased with increas-
ing the polymer concentration (Table 2). There were no 
remarkable differences between the viscosity of the polymer 
solution before and after the milling procedure, which may 
indicate there are no changes in the polymer structure. 10% 
Mel amount in the dispersions increased the viscosity of 
the systems and did not change the flow behavior – they 
remained Newtonian. Adding Mel to the polymer solutions, 
the smallest shift in the viscosity could be detected in case 
of the highest polymer concentration. This can be explained 
by the more considerable viscosity changing effect of the 
polymer concentration than that of the Mel particles. It can 
be concluded that the mechanical influence did not change 
the viscosity of the polymer solutions, and therefore, the 
structure of the PVA chains did not change.
Zeta potential changes
To determine the electrokinetic changes of the diluted dis-
persions, the zeta potential of the samples was measured. 
The results show that the increase of the PVA amount 
decreases the zeta potential in comparison to the sample 
without PVA (Table 3). The main reason for the zeta potential 
reduction can be linked to the nonionic polymer adsorption 
on the surface of the solid particles, which causes a decrease 
of the diffuse layer charge. A greater zeta potential-lowering 
effect can be observed between 0% and 0.25% of PVA than 
between 0.25% and 0.50. At 0.50% of PVA, the surface of 
particles is saturated by the PVA chain; therefore, the change 
of zeta potential is smaller. In case of a higher concentration 
of PVA (.0.50%), the steric hindrance stabilizes the system 
but hampers the disintegration/abrasion of the particles.
investigation of the diluted dispersions to select 
nanosuspension as an intermediate product
raman investigation
Raman spectrograms and chemical maps of raw materials 
and products are presented in Figures 4 and 5. The individual 
spectrum of Mel (a) shows that the absorption peaks are con-
centrated in the region from 1,600 to 1,000 cm-1 (fingerprint 
region), whereas the individual spectra of PVA (b and c) 
Table 2 Viscosity values (η) of the raw PVa solutions before 
milling (PVa %) and after milling (PVa % milled), and the PVa 
solutions after milling with the addition of Mel (Mel PVa % 
milled)
η (mPa⋅s) SD (mPa⋅s)
PVa 2.5% 3.14 0.02
PVa 5.0% 7.38 0.02
PVa 7.5% 20.55 0.07
PVa 2.5% milled 3.12 0.27
PVa 5.0% milled 7.09 0.02
PVa 7.5% milled 20.05 0.07
Mel PVa 2.5% milled 4.42 0.07
Mel PVa 5.0% milled 8.46 0.01
Mel PVa 7.5% milled 21.65 0.07
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol); η, viscosity.
Table 3 Zeta potential values of the diluted dispersions as a 
function of the PVa concentration and particle size distribution 
of Mel (±sD)
Samples Particle size distribution Zeta 
potential 
(mV)
d(0.1) d(0.5) d(0.9)
Particle size (µm)
Mel PVa 0% 2.508±1.100 5.762±2.700 135.640±12.900 -30.7
Mel PVa 0.25% 0.070±0.001 0.150±0.009 1.478±0.0400 -20.9
Mel PVa 0.50% 0.067±0.001 0.130±0.005 0.371±0.010 -16.1
Mel PVa 0.75% 1.235±0.006 2.611±0.018 5.560±0.070 -15.7
Note: d(0.1), d(0.5), d(0.9) is the maximum particle diameter below which 10%, 
50%, and 90%, respectively, of the sample volume exists.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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show just 1 characteristic and extended peak from 3,000 
to 2,800 cm-1. This is the CH stretching vibration region 
that results a medium-to-strong intensity in Raman spectra. 
The spectrograms of diluted dispersions (d, e, and f) show 
the same characteristic region with the spectra of Mel – there 
are no detectable differences among them. Two peaks (one 
more characteristic in 2,437 cm-1 and another smaller one 
in 482 cm-1) appear in the spectra of PVA-containing dis-
persions and in spectra of aqueous Mel dispersion as well. 
The chemical mapping of dried dispersions profiled to this 
peak in 2,437 cm-1 shows that this peak cannot detected 
in this map. This peak can show a dissociated -OH group 
of Enol which is presented when Mel is in an aqueous 
medium, but it is disappeared in dried form, so the change 
is reversible. The chemical map of dispersion profiled to 
Mel spectrogram shows homogenous distribution of Mel. 
It can be summarized that there is no chemical degradation 
or interaction in dispersion which could be detectable with 
Raman technique.
Morphology of particles (scanning electron microscopy)
In order to investigate the effect of milling and PVA amount 
on the morphology of milled Mel, the water was evaporated 
from dispersion and the dried samples were characterized.
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Figure 4 investigation with raman spectroscopy: (A) (a) spectrum of raw Mel, (b) spectrum of raw PVa, (c) spectrum of raw PVa (0.50%) containing solution. 
(B) comparison study of raw materials (Mel and PVa) and the dispersions, (a) spectrum of raw Mel, (b) spectrum of raw PVa, (d) spectrum of dispersion containing 1% Mel 
and 0.25% PVa, (e) spectrum of dispersion containing 1% Mel and 0.50% PVa, (f) spectrum of dispersion containing 1% Mel and 0.75% PVa.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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Figure 5 investigation with raman spectroscopy: (A) comparing raw Mel and aqueous dispersion of Mel- and PVa-containing dispersions, (a) spectrum of raw Mel, (b) 
spectrum of aqueous 1% Mel-containing dispersion without PVa, (c) spectrum of dispersion containing 1% Mel and 0.25% PVa, (d) spectrum of dispersion containing 1% Mel 
and 0.50% PVa, (e) spectrum of dispersion containing 1% Mel and 0.75% PVa. (B) chemical mapping of Mel-containing dispersion (1% Mel and 0.50% PVa) and chemical 
mapping of its dried form profiled to peak in 2,437 cm-1.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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combined wet milling process to produce nanosuspension
Figure 6 shows the raw Mel in physical mixture (Mel 
PVA 0.50% PM) which has an irregular shape with 
34.260±4.860 µm as average particle size. In this PM, the 
PVA particles with size ,6 µm are located on the surface 
of Mel crystals. After drying of the aqueous dispersions, 
the polymer formed non-coherent and coherent think film 
with Mel particles. In case of 0.25% containing PVA (Mel 
PVA 0.25%), the particle size of Mel has decreased, but 
aggregation of the fragmented particles can be observed. 
Mel particles are in homogeneous disperse distribution in 
sample (Mel PVA 0.50%), resulting in ,500 nm (aver-
age particle size: 0.130±0.005 µm). High concentration 
of PVA (Mel PVA 0.75%) helped the recrystallization of 
Mel (nanocrystals with smooth surface) thanks to increased 
solubility of Mel in aqueous PVA solution. Otherwise, the 
sample shows heterogeneous disperse system with nano- and 
microparticles.
crystallinity characterization of Mel in the dried 
dispersions (Dsc and XrPD)
DSC was used to investigate the melting of raw Mel and raw 
PVA and the dried samples (Figure 7). The DSC curve of 
the raw Mel revealed a sharp endothermic peak at 268.66°C, 
reflecting its melting point and an instantly following exo-
thermic peak at 278.09°C can be observed. The DSC curve 
of raw PVA as a semi-crystalline polymer has 2 endothermic 
peaks at 169.51°C and at 222.74°C. The first peak of PVA 
signifies a particular decrystallization of PVA and the second 
peak is the melting temperature.33 The DSC curves of the 
dried products exhibited lower melting points of Mel than 
that of raw Mel. It is connected to the premelting of PVA, 
which induces the earlier melting of Mel in proportion to 
the amount of PVA and decreases the crystallinity degree of 
Mel. Therefore, the XRPD investigation was used to check 
the amorphization of the active agent.
The XRPD investigations justified the change of crystal-
linity degree of Mel in the dispersions with different PVA 
amounts. Figure 8 shows the fingerprints of raw materials 
(Mel and PVA) and the dried dispersions. The samples 
show the characteristic peaks of Mel at 2θ values: 13.06°, 
14.94°, and 18.61°. It was found that the PVA content of 
the samples fundamentally influenced the decrease of the 
crystallinity degree of Mel. As it was established earlier 
in this study, low (2.5%) and high (7.5%) concentrations 
of PVA in the milled dispersion did not result in suitable 
milling efficiency. In this case, the crystallinity degree 
of Mel was 75.82% at low PVA content (2.5%), and it 
decreased to 51.44% at high concentration of PVA (7.5%). 
These results are connected to the milling effectiveness. 
In this study, the 5.0% PVA-containing milled dispersions 
showed smaller crystallinity (13.43%) and the highest 
milling efficiency.
Drug content determination
The spectrophotometrically measured drug content of the sam-
ples was less than the theoretical value (7.5 mg Mel). The drug 
0HO39$
N9PPNî6(8 P N9PPNî6(8 P
0HO39$30
N9PPî6(8 P
N9PPNî6(8 P
0HO39$ 0HO39$
Figure 6 seM pictures of physical mixture (Mel PVa 0.25% PM) and different PVa concentrations containing dried dispersions.
Abbreviations: seM, scanning electron microscopy; Mel, meloxicam; PVa, poly(vinyl alcohol); PM, physical mixture.
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contents, converted to 750 mg dispersion quantity, are 
as follows: 7.36 mg for aqueous sample (without PVA), 
7.19 mg for 0.25% PVA, 7.12 mg for 0.50% PVA, and 
7.23 mg for 0.75%. It can be stated that the washing method 
of the pearls resulted in greater loss of Mel in PVA-containing 
dispersion (3.60%–5.06%) than in case of the aqueous sample 
without PVA (1.80%). The amount of PVA did not signifi-
cantly affect the loss of weight of Mel.
in vitro dissolution study
In case of each sample, the liberation from the hard gela-
tin capsules occurred within 2 sec. Mel has a weak acidic 
character (pK
a
 4.8), and therefore, its solubility in gastric 
juice (pH=1.2) is very poor (1.6±0.2 mg/L, at 37°C). In this 
medium, the greatest dissolved amount of Mel with 0.25% 
and 0.50% PVA content was maximum, 37%, within 20 min 
(Figure 9A). This result is due to the wetting effect of PVA 
(0.25% and 0.50%), which could increase the solubility 
of Mel, and the reduction of the particle size of Mel in the 
dispersions. In contrast, a higher amount of PVA (0.75%) 
hinders the dissolution because a thicker polymer layer is 
formed on the Mel particles.
In intestinal fluid (pH=6.8), the dissolved amount was 
higher in all cases because of the better solubility of Mel 
(0.272±0.001 mg/mL, at 37°C). Figure 9B shows that the 
concentration of PVA influences the amount of dissolved 
/LQ
FRX
QWV
  θVFDOH  
0HO39$0HO 0HO39$39$0HO
Figure 8 XrPD diffractograms of the Mel, PVa, and the dried dispersion.
Abbreviations: XrPD, X-ray powder diffraction; Mel, meloxicam; PVa, poly(vinyl 
alcohol).
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     PLQ
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Figure 7 Dsc curves of raw Mel and PVa and dried dispersions with different PVa concentrations.
Abbreviations: Dsc, differential scanning calorimetry; Mel, meloxicam; PVa, poly(vinyl alcohol).
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combined wet milling process to produce nanosuspension
Mel as in the case of gastric juice, but its extent is bigger. 
In this study, the dispersion containing 0.50% of PVA had 
the most satisfying dissolution behavior from among the 
4 samples. It is followed by the dispersions containing 0.25% 
and 0.75% of PVA, and finally the dispersion without PVA. 
The results justify the need of the polymer (PVA) and the 
correct choice of its quantity.
cell viability assay
Impedance measurement, as a sensitive method to detect 
cellular effects, did not show significant cell damage after 
treatments with Mel, PVA, and Mel formulation groups, as 
reflected by unchanged cell index values (Figure 10). As a 
comparison, cells treated with the detergent Triton X-100 
were lysed and a 100% toxicity was measured. The curves 
show the kinetics of the cellular effects of treatment solu-
tions (Figure 10A), whereas the columns show the effect 
of Mel, PVA and Mel formulations at the 8-h time point 
(Figure 10B).
Permeability study on intestinal barrier model
Caco-2 monolayers showed high TEER values (2,660±181 
Ω×cm2, n=20) before permeability experiments, indicating 
tight barrier properties. The average apparent permeability 
coefficients of marker molecules were also low (fluores-
cein: 0.81±0.13×10-6 cm/s; albumin: 0.08±0.03×10-6 cm/s), 
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Figure 9 In vitro dissolution curves of Mel in artificial gastric juice (A) and intestinal juice (B).
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).








    7LPHK
1RU
PDO
L]HG
FHO
OLQG
H[
39$0HO
&RQWURO 39$39$0HO 0HO39$0HO 7;





 &RQWURO    39$ 0HO 7;
1
RUP
DOL]
HGF
HOOL
QGH
[
RI39$LQ0HOIRUPXODWLRQV
%$
Figure 10 cell viability kinetics (A) and results 8 h after treatment (B) in caco-2 intestinal epithelial cells with Mel, PVa, and formulations measured by impedance.
Notes: Values are presented as mean±sD, n=6–12. Statistical analysis: ANOVA followed by Dunett’s test. Statistically significant differences are: ***p,0.001, compared to 
control group.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol); TX-100, Triton X-100; anOVa, analysis of variance.
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in agreement with the TEER values and the formation of 
tight cell layers.
The permeability of Mel suspension and Mel formulations 
was significantly higher than that of marker molecules. The 
penetration of Mel from the 3 investigated products across 
cell layers was significantly increased as compared to Mel 
suspension. From all the tested samples, the P
app
 value of 
Mel was the highest in the formulation containing 0.05% 
PVA (Figure 11).
holding time determination
Since the investigated dispersions are intermediate products, 
the change of particle size distribution and the crystallinity 
index are very important during storage. In general, the time 
period before the dispersion used for the preparation of differ-
ent dosage forms is 1 or 2 h, or possibly longer. The measure-
ments have proven that 0.50% of PVA-containing dispersion 
had no significant changes in the particle size, particle 
size distribution, and crystallinity up to 2 weeks (Table 4).
Conclusion
Based on our results, it can be stated that the combination 
of planetary ball mill and the pearl milling technology is 
a new possibility to nanonize the Mel as a nonsteroidal 
anti-inflammatory agent to reach the particle size range of 
100–500 nm. This combinative wet technology resulted 
in significant particle size reduction without premilling 
(pretreatment of raw agent). In addition to the process 
parameters (the pearl amount, the milling time, and the 
rotation speed of jar), the amount of PVA was also a critical 
parameter because it affected the milling effectiveness, the 
particle size distribution, and the crystallinity of Mel. The 
different concentrations of PVA in the aqueous dispersion 
also influenced the viscosity and the electrokinetic property 
of the particle, according the DLVO theory,34 and thus, the 
stability of the dispersions.
It was found that the milling effectiveness of low con-
centration of PVA (,4%) was not satisfactory, because the 
crushing/breaking effect of the pearls was less prevalent. High 
concentration of PVA (.5%) also resulted in unsatisfactory 
milling effectiveness because of the formation of polymer 
layer on surface of particles, which protects the particles from 
the fragmentation. In connection with this, the crystallinity 
of Mel decreased with the increase of milling effectiveness, 
which plays an important role in the fast drug release.
In this work, the combined wet milling process was also 
used successfully to prepare Mel-containing nanosuspen-
sion as an intermediate product to design the final dosage 
form(s) for per oral administration. The optimized process 
parameters (1:1 ratio of predispersion and pearls, 437 rpm, 
and 43 min) resulted in 200-fold particle size reduction 
of Mel. Considering the effectiveness of milling, 5% PVA 
was proved to be an optimal quantity to meet the expected 
value (100–500 nm). The optimized nanosuspension (1% 
Mel and 0.50% PVA) as an intermediate product showed a 
stable system with 2 weeks of holding time.
The human Caco-2 cell culture studies justified that the 
penetration of Mel from different PVA-containing products 
was significantly increased as compared to Mel suspension 
without toxic effects. From all the tested samples, the P
app
 
value of Mel was the highest in the investigated sample 
containing 0.05% PVA, which belongs to the optimized 
nanosuspension.
Based on the above results, the milling process and the 
composition of the nanosuspension can be recommended 
to produce innovative dosage forms (eg, capsule) with fast 
dissolution rate of Mel. During the development of dosage 
form(s), the stabilization of the amorphous Mel particle may 
Table 4 Particle size distribution changes (µm) during the stability 
testing
 Day 0 2 weeks
d(0.1) d(0.5) d(0.9) d(0.1) d(0.5) d(0.9)
Mel PVa 0.25% 0.070 0.150 1.478 0.080 0.152 2.073
Mel PVa 0.50% 0.067 0.136 0.371 0.068 0.140 0.427
Mel PVa 0.75% 1.207 2.232 5.224 0.244 2.611 5.560
Note: d(0.1), d(0.5), d(0.9) is the maximum particle diameter below which 10%, 
50%, and 90%, respectively, of the sample volume exists.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol).
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Figure 11 evaluation of permeability of Mel across caco-2 epithelial cell layers 
treated with Mel and optimized Mel PVa formulations for 1 h.
Notes: Values are presented as mean±sD, n=4. statistical analysis: anOVa 
followed by Bonferroni posttest. Statistically significant differences are: ***p,0.001, 
compared to control group; ###p,0.001 compared to the indicated columns.
Abbreviations: Mel, meloxicam; PVa, poly(vinyl alcohol); Papp, apparent permeability 
coefficients.
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combined wet milling process to produce nanosuspension
also be an important viewpoint to ensure the dissolution 
profile of the active ingredient.
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